4.8 Article

Distinct Early Serological Signatures Track with SARS-CoV-2 Survival

Journal

IMMUNITY
Volume 53, Issue 3, Pages 524-+

Publisher

CELL PRESS
DOI: 10.1016/j.immuni.2020.07.020

Keywords

-

Categories

Funding

  1. Ragon Institute of MGH, MIT and Harvard
  2. Massachusetts Consortium on Pathogen Readiness (MassCPR)
  3. Bill and Melinda Gates Foundation [235730]
  4. NIAID [U19 AI135995]
  5. Centers for Disease Control and Prevention [CK000490]

Ask authors/readers for more resources

As SARS-CoV-2 infections and death counts continue to rise, it remains unclear why some individuals recover from infection, whereas others rapidly progress and die. Although the immunological mechanisms that underlie different clinical trajectories remain poorly defined, pathogen-specific antibodies often point to immunological mechanisms of protection. Here, we profiled SARS-CoV-2-specific humoral responses in a cohort of 22 hospitalized individuals. Despite inter-individual heterogeneity, distinct antibody signatures resolved individuals with different outcomes. Although no differences in SARS-CoV-2-specific IgG levels were observed, spike-specific humoral responses were enriched among convalescent individuals, whereas functional antibody responses to the nucleocapsid were elevated in deceased individuals. Furthermore, this enriched immunodominant spike-specific antibody profile in convalescents was confirmed in a larger validation cohort. These results demonstrate that early antigen-specific and qualitative features of SARS-CoV-2-specific antibodies point to differences in disease trajectory, highlighting the potential importance of functional antigen-specific humoral immunity to guide patient care and vaccine development.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available